PE20091575A1 - Derivados bifenilo como inhibidores del virus de la hepatitis c - Google Patents

Derivados bifenilo como inhibidores del virus de la hepatitis c

Info

Publication number
PE20091575A1
PE20091575A1 PE2009000198A PE2009000198A PE20091575A1 PE 20091575 A1 PE20091575 A1 PE 20091575A1 PE 2009000198 A PE2009000198 A PE 2009000198A PE 2009000198 A PE2009000198 A PE 2009000198A PE 20091575 A1 PE20091575 A1 PE 20091575A1
Authority
PE
Peru
Prior art keywords
imidazol
pyrrolidinyl
alkyl
hepatitis
virus
Prior art date
Application number
PE2009000198A
Other languages
English (en)
Inventor
Carol Bachand
Daniel H Deon
Jason Goodrich
Rico Lavoie
Alain Martel
Van N Nguyen
Edward H Ruediger
Makonen Belema
Andrew C Good
Clint A James
Omar D Lopez
Nicholas A Meanwell
Jeffrey Lee Romine
Lawrence B Snyder
Laurent Denis R St
David R Langley
Lawrence G Hamann
Fukang Yang
Gan Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20091575A1 publication Critical patent/PE20091575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN COMPUESTO BIFENILO DE FORMULA (I), DONDE D Y E SON UN ANILLO AROMATICO DE 5 MIEMBROS QUE CONTIENE 1 a 3 HETEROATOMOS DE N, S U O; R1 Y R1' SON HALO, OH, FORMILO, ENTRE OTROS; R2 Y R2' JUNTO A LOS ATOMOS DE CARBONO A LOS QUE ESTAN UNIDOS FORMAN UN ANILLO DE 5 A 8 MIEMBROS QUE OPCIONALMENTE CONTIENE 1 O 2 HETEROATOMOS DE N, S U O Y QUE ESTA OPCIONALMENTE SUSTITUIDO CON CARBOXI, FORMILO, ENTRE OTROS; R3 Y R3' SON H, ALCOXIALQUILO C1-C6, ALCOXICARBONILO C1-C6, ENTRE OTROS; R4 Y R4' SON (a), (b) O (c); X ES O, S, ENTRE OTROS; R5 ES ALCOXI C1-C6, ALQUILO C1-C6, ENTRE OTROS; R6 ES H, R10-C(O)-, R10-C(S)-; R7 ES H O ALQUILO C1-C6; R8 Y R9 SON H, ALQUENILO C2-C6, ENTRE OTROS; R10 ES ALCOXI C1-C6, ALQUILO C1-C6, ENTRE OTROS; m ES DE 0 A 2; o ES DE 1 A 3; s ES DE 0 A 4; u Y u' SON 0 O UN ENTERO DE 1 A 3. SON COMPUESTOS PREFERIDOS: ((1S)-1-(((2S)-2-(5-(9-(2-((2S)-1-((2S)-2-((METOXICARBONIL)AMINO)-3-METILBUTANOIL)-2-PIRROLIDINIL)-1H-IMIDAZOL-5-IL)-6-METIL-6,7-DIHIDRO-5H-DIBENZO[c,e]AZEPIN-3-IL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)CARBONIL)-2-METILPROPIL)CARBAMATO DE METILO, ((1S)-1-(((2S)-2-(5-(7-(2-((2S)-1-((2S)-2-((METOXICARBONIL)AMINO)-3-METILBUTANOIL)-2-PIRROLIDINIL)-1H-IMIDAZOL-5-IL)-9-OXO-9H-FLUOREN-2-IL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)CARBONIL)-2-METILPROPIL)CARBAMATO DE METILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA FUNCION DE PROTEINA NS5A CODIFICADA POR EL VIRUS DE LA HEPATITIS C (VHC)
PE2009000198A 2008-02-13 2009-02-11 Derivados bifenilo como inhibidores del virus de la hepatitis c PE20091575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2826608P 2008-02-13 2008-02-13

Publications (1)

Publication Number Publication Date
PE20091575A1 true PE20091575A1 (es) 2009-11-04

Family

ID=40409903

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000198A PE20091575A1 (es) 2008-02-13 2009-02-11 Derivados bifenilo como inhibidores del virus de la hepatitis c

Country Status (27)

Country Link
US (1) US7704992B2 (es)
EP (1) EP2242750B1 (es)
JP (1) JP5425815B2 (es)
KR (1) KR101614964B1 (es)
CN (1) CN101998954B (es)
AR (1) AR070365A1 (es)
AU (1) AU2009215105B2 (es)
BR (1) BRPI0908456A2 (es)
CA (1) CA2715550C (es)
CL (1) CL2009000323A1 (es)
CO (1) CO6251260A2 (es)
CY (1) CY1114298T1 (es)
DK (1) DK2242750T3 (es)
EA (1) EA020511B1 (es)
ES (1) ES2415208T3 (es)
HK (1) HK1144195A1 (es)
HR (1) HRP20130421T1 (es)
IL (1) IL207258A0 (es)
MX (1) MX2010008531A (es)
NZ (1) NZ586990A (es)
PE (1) PE20091575A1 (es)
PL (1) PL2242750T3 (es)
PT (1) PT2242750E (es)
SI (1) SI2242750T1 (es)
TW (1) TWI423798B (es)
WO (1) WO2009102568A1 (es)
ZA (1) ZA201005485B (es)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240614A (en) * 1992-01-10 1993-08-31 Baxter International Inc. Process for removing unwanted materials from fluids and for producing biological products
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2486181C2 (ru) * 2007-07-05 2013-06-27 Эррэй Биофарма Инк. Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
MX2010008699A (es) * 2008-02-12 2010-08-30 Bristol Myers Squibb Co Derivados heterociclicos como inhibidores de virus de la hepatitis c.
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102264737A (zh) * 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
RU2505539C2 (ru) * 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8420686B2 (en) * 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8242156B2 (en) * 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010094977A1 (en) * 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
CA2753382C (en) 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
PE20120773A1 (es) * 2009-03-27 2012-07-19 Presidio Pharmaceuticals Inc Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) * 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) * 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
EP2430015B1 (en) * 2009-05-12 2015-06-17 Merck Sharp & Dohme Corp. Fused tricyclic compounds useful for the treatment of viral diseases
RS54386B8 (sr) * 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
WO2010138790A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US8211928B2 (en) * 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010138791A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EA020031B1 (ru) * 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
MX2012000695A (es) 2009-07-16 2012-06-12 Vertex Pharma Análogos de bencimidazol para el tratamiento o la prevención de infecciones por flavivirus.
CN102480971B (zh) 2009-09-04 2014-11-26 杨森制药公司 化合物
WO2011031934A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US9156818B2 (en) * 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20110137633A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
EP2512480A4 (en) * 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112012014899A2 (pt) 2009-12-18 2017-03-14 Idenix Pharmaceuticals Inc composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
WO2011075607A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG188957A1 (en) 2010-01-25 2013-05-31 Enanta Pharm Inc Hepatitis c virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) * 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
CA2791630A1 (en) * 2010-03-04 2011-09-09 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of hcv replication
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
UY33473A (es) 2010-06-28 2012-01-31 Vertex Pharma Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
CN103459399A (zh) * 2010-09-29 2013-12-18 默沙东公司 用于治疗丙型肝炎病毒感染的四环吲哚衍生物
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
BR112013007696A2 (pt) * 2010-09-29 2019-09-24 Merck Sharp & Dohme composto, composição farmacêutica, usos do referido composto e da referida composição
SG189985A1 (en) 2010-10-26 2013-06-28 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
EP2640719B1 (en) 2010-11-17 2017-05-10 Gilead Pharmasset LLC Antiviral compounds
EP2651928A4 (en) * 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012122716A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
TWI482766B (zh) * 2011-07-09 2015-05-01 Sunshine Lake Pharma Co Ltd As a spiro compound for hepatitis C virus inhibitors
WO2013016490A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013021344A1 (en) * 2011-08-08 2013-02-14 Lupin Limited Imidazole derivatives as antiviral agents
WO2013028953A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
EA026667B9 (ru) 2011-09-16 2017-07-31 Джилид Фармассет Ллс Фармацевтическая композиция для лечения вируса гепатита с
EA037883B1 (ru) 2011-11-16 2021-05-31 Джилид Фармассет Ллс Противовирусные соединения
ES2558608T3 (es) 2011-12-28 2016-02-05 Janssen Sciences Ireland Uc Derivados hetero-bicíclicos como inhibidores del VHC
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
IN2014MN01547A (es) 2012-02-10 2015-05-08 Lupin Ltd
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
WO2014082380A1 (en) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2014110688A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases
WO2014120981A1 (en) 2013-01-31 2014-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
WO2015089810A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015096674A1 (zh) * 2013-12-23 2015-07-02 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104803989B (zh) 2014-01-23 2017-12-22 广东东阳光药业有限公司 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
CN105985355B (zh) * 2015-03-01 2020-05-05 南京圣和药业股份有限公司 稠合三环类肝炎病毒抑制剂及其应用
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
GB2552919A (en) * 2015-11-18 2018-02-21 Azad Pharmaceutical Ingredients Ag Stable amorphous form of daclatasvir
WO2018032467A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
KR101887969B1 (ko) * 2016-08-30 2018-08-13 한국과학기술연구원 항바이러스 활성을 가지는 카르바졸 화합물
CN106543151B (zh) * 2016-10-18 2018-10-30 山东师范大学 一种基于Co（Ⅱ）的金属有机框架及其制备方法与应用
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
JP2022510407A (ja) 2018-12-04 2022-01-26 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
AU2022279234A1 (en) 2021-05-21 2023-12-07 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679153A4 (en) 1993-01-14 1996-05-15 Magainin Pharma FINALLY MODIFIED AMINO ACIDS AND PEPTIDES.
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
AU6680998A (en) * 1997-03-05 1998-09-22 Trimeris Inc. Benzanthrone compounds and antiviral uses thereof
WO2005016343A1 (en) * 2003-08-11 2005-02-24 The Regents Of The University Of California Novel anti-viral agents based upon derivatives of the aromatic heterocycle phenanthridine
US7894996B2 (en) 2005-02-28 2011-02-22 The Rockefeller University Structure of the hepatitis C NS5A protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
PT1940786E (pt) 2005-09-16 2010-10-04 Arrow Therapeutics Ltd Derivados de bifenilo e sua utilização no tratamento de hepatite c
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
RU2008128453A (ru) * 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
CA2653924A1 (en) 2006-05-30 2007-12-06 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) * 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C

Also Published As

Publication number Publication date
KR20100121651A (ko) 2010-11-18
DK2242750T3 (da) 2013-07-29
CN101998954A (zh) 2011-03-30
CO6251260A2 (es) 2011-02-21
SI2242750T1 (sl) 2013-08-30
WO2009102568A1 (en) 2009-08-20
EP2242750A1 (en) 2010-10-27
ES2415208T3 (es) 2013-07-24
KR101614964B1 (ko) 2016-04-22
AR070365A1 (es) 2010-03-31
EA201001275A1 (ru) 2011-06-30
CN101998954B (zh) 2015-06-03
IL207258A0 (en) 2010-12-30
BRPI0908456A2 (pt) 2019-09-24
MX2010008531A (es) 2010-08-30
CY1114298T1 (el) 2016-08-31
US7704992B2 (en) 2010-04-27
AU2009215105A1 (en) 2009-08-20
EP2242750B1 (en) 2013-04-24
NZ586990A (en) 2012-04-27
PL2242750T3 (pl) 2013-09-30
AU2009215105B2 (en) 2013-09-26
EA020511B1 (ru) 2014-11-28
ZA201005485B (en) 2012-01-25
CL2009000323A1 (es) 2010-08-20
JP2011511837A (ja) 2011-04-14
HRP20130421T1 (en) 2013-06-30
CA2715550C (en) 2016-09-20
PT2242750E (pt) 2013-06-28
HK1144195A1 (en) 2011-02-02
JP5425815B2 (ja) 2014-02-26
TW200938191A (en) 2009-09-16
TWI423798B (zh) 2014-01-21
US20090202483A1 (en) 2009-08-13
CA2715550A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
PE20091575A1 (es) Derivados bifenilo como inhibidores del virus de la hepatitis c
PE20120993A1 (es) Derivados bifenilicos como antivirales
PE20081583A1 (es) Agentes antibacterianos derivados de compuestos carbonilamino
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR063684A1 (es) Derivados de 4, 4´-bifenildiilbis(1h-imidazol-5, 2-diil) como inhibidores del virus de la hepatitis c, composicion que los comprende y su uso para tratar una infeccion con vhc.
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
TW200637559A (en) 3-propenylcefem derivative
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
ES2578302T3 (es) Compuestos de 5,6-dihidro-1H-piridin-2-ona
PE20080689A1 (es) Derivados de amina inhibidores de quinasa
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
PE20090042A1 (es) Analogos de ciclopamina
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20120258A1 (es) Derivados de bencimidazol-pirrolidina como inhibidores del virus de la hepatitis c
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
PE20140961A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
CR7548A (es) Derivados de triazole como antagonistas del receptor de tachykinin
PE20120557A1 (es) Compuestos derivados de (5r)-10, 10-dimetil-7-azadispiro[3.0.4.1]decan-8-carboxamida como inhibidores del virus de la hepatitis c
CL2004000076A1 (es) Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed